ClinicalTrials.gg
Not yet recruitingNCT07129837Anti-pcolce/RAUpdated Aug 24, 2025

Serum Anti-PCOLCE as Novel Diagnostic Biomarker in Rheumatoid Arthritis With Emphasis on Seronegative Patients.

An observational study in Rheumatoid Arthritis, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
62
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Arthritis, Rheumatoid by Assiut University — 22 open to participants now, 22 under way, none of them phase 3. Arthritis, Rheumatoid · Assiut University.

Planned enrollment
35th of 43
62 · median 80
Started
2026
with 9 others
Observational
43 of 49
21 open now
Primary completion
2027-03
later than 12 of 21 live
Registered
37th of 49
by date

Among the 49 studies in Arthritis, Rheumatoid by Assiut University, this one is the 35th largest by planned enrollment of the 43 observational ones that give a count, is one of 10 that started in 2026, is one of 43 observational ones, reaches primary completion later than 12 of the 21 other live ones, and was the 37th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

22 of the 49 studies in Arthritis, Rheumatoid by Assiut University are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Arthritis, Rheumatoid by Assiut University, or all of them as a file.
02

Study summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects synovial joints, leading to pain, swelling, and progressive joint damage. Early diagnosis is critical to prevent irreversible disability. However, up to 30% of RA patients are seronegative for conventional markers such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, creating a diagnostic challenge. This study aims to evaluate the diagnostic performance of serum anti-procollagen C-endopeptidase enhancer (anti-PCOLCE) antibodies in RA patients, with a particular focus on seronegative cases. We will conduct a case-control study involving RA patients and age- and sex-matched healthy controls. Clinical assessments, disease activity scoring, functional disability evaluation, and laboratory testing will be performed. The findings may provide evidence for anti-PCOLCE as a novel biomarker for improved RA diagnosis.

Read the detailed description

Rheumatoid arthritis (RA) is an inflammatory disease that primarily affects synovial joints through an autoimmune mechanism. If not treated properly, the disease can lead to bone erosion, joint deformities, and disability. Arthritis can also cause serious extra-articular disorders, including interstitial lung disease, vasculitis, and lymphoma.

The global prevalence of RA is 1%, with 44% of patients incapacitated within ten years. Increasing evidence indicates that early diagnosis and treatment of RA are crucial in preventing or delaying progression to erosive disease.

The production of antibodies to modified self-antigens is a hallmark in RA damage to synovial joints. The diagnosis of RA is based on a combination of clinical, radiographic, and serological findings. Among serological biomarkers, the most widely used are rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. While anti-CCP antibodies are relatively specific for RA and are included in the 2010 ACR/EULAR classification criteria, they are not present in all patients. Approximately 20-30% of RA patients may test negative for both RF and anti-CCP, is termed seronegative RA (SNRA) emphasizing the need for additional, more sensitive and specific biomarkers, especially in early and seronegative RA.

Antibodies to citrullinated and carbamylated proteins are of particular interest in RA because of their high prevalence, specificity, association with erosive disease, and appearance during the preclinical phase of RA. Citrullination is a physiological posttranslational modification (PTM) best known for its role in gene regulation and skin keratinization. During this process, arginine residues are converted to citrulline by the activity of the peptidylarginine deiminase (PAD) enzymes.

Procollagen C-protease enhancer protein (PCOLCE) is a secretory glycoprotein, which plays an important role in enhancing the activity of procollagen C-Protease and promoting the reconstruction of extracellular matrix.

PCOLCE essential for the maturation of collagen, particularly types I and II. These collagen types are major components of articular cartilage and connective tissues. In the inflammatory environment of RA, PCOLCE can undergo citrullination, potentially converting it into a novel autoantigen.

Emerging evidence suggests that PCOLCE may elicit an autoimmune response in RA patients. Detecting autoantibodies directed against PCOLCE (anti- PCOLCE ) could therefore provide a new serological tool for RA diagnosis. These antibodies may not only enhance diagnostic accuracy particularly in patients who are seronegative for conventional markers but also shed light on novel mechanisms in RA pathophysiology.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid arthritis
  • Seronegative
  • Elisa
  • Anti-pcolce
  • Biomarker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Two groups will be included: rheumatoid arthritis patients attending the Rheumatology, Rehabilitation and Physical Medicine Department at Assiut University Hospital, and age- and sex-matched healthy controls recruited from the community.

Eligibility criteria

Inclusion criteria Adults (≥18 years old).

Patients clinically diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria:

Exclusion criteria Patients with other or connective tissue diseases (e.g., SLE, SS). Patients with chronic infections or . Patients less than 18 years old.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
62 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Rheumatoid Arthritis Patients

    Adult patients (≥18 years) diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria.

    Diagnostic Test: Clinical evaluation, disease activity and disability scoring, and laboratory testing including RF, anti-CCP, and serum anti-PCOLCE antibody measurement by ELISA.

  • Healthy Controls

    Age- and sex-matched healthy individuals without rheumatoid arthritis or other autoimmune diseases.

Interventions

  • Diagnostic testClinical evaluation, disease activity and disability scoring, and laboratory testing including RF, anti-CCP, and serum anti-PCOLCE antibody measurement by ELISA.

    For rheumatoid arthritis (RA) patients: participants will undergo comprehensive clinical evaluation including demographic data, detailed history, musculoskeletal and systemic examination, assessment of disease activity using DAS-28 score, functional disability evaluation by modified Health Assessment Questionnaire (mHAQ), and laboratory investigations including CBC, ESR, CRP, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, and serum anti-procollagen C-endopeptidase enhancer (anti-PCOLCE) antibodies measured by ELISA. For healthy controls: participants will undergo comprehensive clinical evaluation including demographic data, detailed history, musculoskeletal and systemic examination, and laboratory testing limited to serum anti-PCOLCE antibodies measured by ELISA.

    Also known as: Serum anti citrullinated procollagen c endopeptidase enhancer anti-bodies., Serum Anti-pcolce

06

What researchers measure

Primary outcomes

  1. Serum anti-PCOLCE antibody levels in rheumatoid arthritis patients versus healthy controls

    To measure serum level of anticitrullinated procollagen C endopeptidase enhancer antibody (anti-PCOLCE) in RA patients compared to healthy controls . To assess the diagnostic performance of anti PCOLCE for RA specifically seronegative RA patients.

    Time frame: Baseline (at the time of enrollment)

  2. measure serum level of anticitrullinated procollagen C endopeptidase enhancer antibody (anti-PCOLCE) in RA patients compared to healthy controls .

    To measure serum level of anticitrullinated procollagen C endopeptidase enhancer antibody (anti-PCOLCE) in RA patients compared to healthy controls . To assess the diagnostic performance of anti PCOLCE for RA specifically seronegative RA. To evaluate correlation of serum anti-PCOLCE level with disease activity and functional disability scores in RA patients .

    Time frame: At baseline (single measurement at enrollment).

Secondary outcomes

  1. Correlation between serum anti-PCOLCE antibody levels and disease activity scores in RA patients

    To assess the relationship between serum anti-procollagen C-endopeptidase enhancer (anti-PCOLCE) antibody levels and clinical disease activity and functional disability scores in RA patients , measured by DAS28-ESR, CDAI, and HAQ-DI scores.

    Time frame: At baseline (single assessment at enrollment).

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, Huizinga TW, van der Helm-van Mil AH. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009 Aug;60(8):2262-71. doi: 10.1002/art.24661. PubMed 19644846 ↗
  • Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: Extra-articular manifestations and comorbidities. Autoimmun Rev. 2021 Apr;20(4):102776. doi: 10.1016/j.autrev.2021.102776. Epub 2021 Feb 17. PubMed 33609792 ↗
  • Maska L, Anderson J, Michaud K. Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S4-13. doi: 10.1002/acr.20620. No abstract available. PubMed 22588760 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Mar 2027, 10 months later.

Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 10 months is below that.

Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 19, 2025
StartEst.
May 2026
Primary completionEst.
Mar 2027
CompletionEst.
May 2027
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07129837
Lead sponsor
Assiut University
Collaborators
World Health Organization
Responsible party
Mariam Rezk Lyas Ibrahim (Principal investigator, Assiut University) — Principal investigator
First posted
Aug 19, 2025
Start date
May 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 24, 2025

Study contacts

Mariam Rezk Lyas Ibrahim, M.B.B.Ch
Contact
mariamrezkrh@gmail.com
+20 01115938529
Sara Farrag Ahmed, Lecturer
Contact
sara_farrag@aun.edu.eg
+20 01097767735

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion